Adage Capital Partners GP L.L.C. Has $21.28 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Adage Capital Partners GP L.L.C. lowered its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 36.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 175,000 shares of the biotechnology company's stock after selling 100,000 shares during the period. Adage Capital Partners GP L.L.C. owned about 0.18% of Sarepta Therapeutics worth $21,278,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SRPT. Manchester Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 156 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth about $36,000. Steward Partners Investment Advisory LLC boosted its holdings in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after buying an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after buying an additional 216 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 7.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft dropped their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Scotiabank cut their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research note on Thursday, March 20th. HC Wainwright reaffirmed a "neutral" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, April 16th. Piper Sandler cut their price objective on Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. Finally, Morgan Stanley lowered their target price on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a report on Friday, April 11th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.70.

Sarepta Therapeutics Trading Down 1.1 %

Shares of SRPT traded down $0.66 during trading hours on Tuesday, hitting $60.85. The stock had a trading volume of 1,993,197 shares, compared to its average volume of 1,428,332. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market cap of $5.90 billion, a P/E ratio of 48.68 and a beta of 0.93. The company's fifty day simple moving average is $75.46 and its 200 day simple moving average is $104.84. Sarepta Therapeutics, Inc. has a 12-month low of $48.01 and a 12-month high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.